Arcus Biosciences

Cartoon of businessmen standing around a broken target
Biotech

Arcus halts Gilead-partnered TIGIT trials as it reworks R&D

A key late-stage trial of Arcus Biosciences and Gilead’s anti-TIGIT antibody domvanalimab has flopped.
Ben Adams Dec 12, 2025 10:00am
Gut stomach

Gilead, Arcus keep TIGIT dream alive with 27-month OS data

Oct 13, 2025 7:05am
Return To Sender stamp on an envelope

Gilead hands back one Arcus cancer candidate from $725M deal

Aug 7, 2025 6:35am
Graphic showing arrows missing the bullseye on a target

How 'overenthusiasm' led to Big Pharma's risky $6B TIGIT gamble

Jun 13, 2025 8:00am
Gilead

Gilead loses interest in Arcus' rival to Merck's Welireg

Feb 18, 2025 8:19am
photo of a paraglider in the foreground with the alps in the background

Flagship vet plants CEO roots at Pharming—Chutes & Ladders

Jan 24, 2025 8:30am